Trial By Error: CBT and Irritable Bowel Syndrome

Online CBT for IBS: Going to be a big money spinner for RMM:

https://www.s4me.info/threads/proto...der-moss-morris-et-al.7965/page-8#post-230272

 

Trial By Error: A Commercial Deal for King’s College London’s IBS-CBT Digital Program

http://www.virology.ws/2020/01/27/t...ings-college-londons-ibs-cbt-digital-program/

 

So by 24 weeks there wasn't much of an improvement, whereas at 12 there was a little more? Doesn't that rather suggest the effects wear off quickly?

 

That should have been "months." It has been corrected! They wear off, but not quite that quickly.

 

Glad to see that the word prestigious (as applied in a post above) seems to have reverted its original meaning of "practising conjuring tricks".

 

Ah. That makes more sense. But it's still short of a cure.

 

COI from the PRINCE trial (Persistent physical symptoms reduction intervention: a system change and evaluation (PRINCE)—integrated GP care for persistent physical symptoms: protocol for a feasibility and cluster randomised waiting list, controlled trial)

https://bmjopen.bmj.com/content/9/7/e025513

 

I didn't realise before that Peter White was also involved in the IBS cbt research

https://gut.bmj.com/content/68/9/1613

 

Yes, it's always good to read the fine print!

 

Looking on the Mahana Therapeutics website, it seems that originally the web version of Prof Moss-Morris's self management manual for CBT for IBS was called Regul8 but is now renamed Parallel on the Mahana Therapeutics website:


https://www.kcl.ac.uk/ioppn/depts/p...earchGroupings/healthpsych/research-group/IBS

"Irritable Bowel Syndrome Overview

Irritable Bowel Syndrome (IBS) affects 10–22% of the UK population. Current treatment relies on a positive diagnosis, reassurance, lifestyle advice and drug therapies, but many suffer on-going symptoms. Professor Moss-Morris has developed a CBT based self-management manual for treating IBS in primary care with minimal therapist contact. In collaboration with colleagues in Southampton, and funded through NIHR RfPB, a web version of this treatment approach was developed called Regul8. Publications from modelling work for the intervention and trials of the approaches are listed below "


Now called Parallel on the Mahana Therapeutics website :

https://www.mahanatx.com/treatments/parallel

"Parallel, formerly known as Regul8, originally was developed by Rona Moss-Morris Ph.D, Head of Psychology Department, King’s College London (KCL) in collaboration with Trudie Chalder, Ph.D, Professor of Cognitive Behavioural Psychotherapy and Alice Sibelli, Ph.D. at KCL and Dr. Hazel Everitt, Professor of Primary Care Research, University of Southampton. Initial clinical funding support was provided by the UK National Institute for Health Research (NIHR)"

..........................

And on that same link:

"The Parallel Approach

For years, CBT has been used successfully to treat health issues like chronic pain (4) heart disease (5) and multiple sclerosis (6). Parallel takes CBT online to help reduce the severity of IBS.


Parallel Clinical Trial

The Parallel program was tested in the world’s largest (n=558) randomized, controlled trial of Cognitive Behavioral Therapy for IBS (the “ACTIB” Trial) 3. The outcomes were dramatic and potentially game-changing for patients. Starting at just 3 months, patients experienced significant and clinically meaningful reduction in the severity of their IBS.

At 12 months 66% of patients reported significant and clinically meaningful reduction in the severity of their IBS .

On average, reduction in IBS severity was twice that of patients receiving medical care as usual.

3. Everett et al. Gut. 2019 Sep;68(9):1613-1623."

.....................

They are in the process of developing CBT treatments for IBD:

https://www.mahanatx.com/treatments/ibd-research

"A New Way to Treat IBD

Mahana is currently developing a personalized digital treatment for adolescents and adults with Inflammatory Bowel Disease. This product will be tested in a series of research studies and randomized, controlled trials. This treatment will tap into the power of Cognitive Behavioral Therapy (CBT) to help patients living with IBD."

..........................

https://www.mahanatx.com/publications

"Publications

A Decade of Peer-reviewed Research

Mahana is committed to developing safe and effective products. Below are links to peer-reviewed publications for Parallel1, our IBS treatment. Studies for our IBD treatment are in progress."

 

Hey thanks for posting this. I will look at that next. sounds like might be interesting bad claims being made

 

So now they're claiming CBT is effective as a primary treatment rather than an adjunct therapy. At least this is how that reads to me. Deliberately misleading.

 

I wasn't sure if it was deliberately misleading or just written badly by an intern. And then not carefully vetted.

 

Either way, it's misleading and the company who published it are responsible.

In my old job any document being written for, or shared with other departments or clients had to be proof read by two people. At least one of those had to be technically competent enough to catch tech errors and the other focusing on misleading wording. Otherwise you could be leaving yourself open to disputes and damaged client relationships or even financial penalties.

Very, very sloppy. Funny how the sloppiness with language always works to try to make their therapy look more effective than it actually is.

 

AYFKM?

Was commercializing this always the intent? I would bet it was and that it is possible to establish the timeline for this. This is very similar to the intent with commercializing the PACE trial with OneHealth, again with Chalder on the board of directors.

e: derped acronym

 

I don't know if it's worth pointing them out, there are so many, but there was this in the CoI declaration that, yet again, says the quiet part loud. It's really weird that FND folks still pretend they don't mean psychogenic when they admit to it all the time.

 

He was also involved in a commercial venture to promote the BPS model with Chalder while they were doing PACE.

I'm sure that's a happy coincidence that did not have any impact whatsoever on the research and that assurances were given to the editors who saw no reason to be concerned.

 

Good grief. IBD is on a whole other level. Are they deliberately trying to get people killed for profit?